Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.51 |
| ▸ | CASP6 | P55212 | 3/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.51 |
| ▸ | CA12 | O43570 | 1/20 | 0.49 |
| ▸ | CA1 | P00915 | 1/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
| ▸ | CA4 | P22748 | 1/20 | 0.49 |
| ▸ | CA6 | P23280 | 1/20 | 0.49 |
| ▸ | CA5A | P35218 | 1/20 | 0.49 |
| ▸ | CA7 | P43166 | 1/20 | 0.49 |
| ▸ | CA9 | Q16790 | 1/20 | 0.49 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.49 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.49 |
| ▸ | NT5E | P21589 | 4/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | NSD2 | O96028 | 3/20 | 0.42 |
| ▸ | SNCA | P37840 | 2/20 | 0.42 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5734698 | 0.83 | CA1 (0.68) | HSD17B10ALDH1A1CASP6CYP2C9CYP2C19 | |
| SCHEMBL1893729 | 0.81 | LMNA (0.60) | HSD17B10ALDH1A1CASP6CYP2C9CYP2C19 | |
| SCHEMBL29429154 | 0.81 | LMNA (0.60) | HSD17B10ALDH1A1CASP6CYP2C9CYP2C19 | |
| SCHEMBL565054 | 0.81 | LMNA (0.60) | HSD17B10ALDH1A1CASP6CYP2C9CYP2C19 | |
| SCHEMBL574853 | 0.79 | LMNA (0.58) | HSD17B10ALDH1A1CASP6CYP2C9CYP2C19 | |
| Ammonia Solution, Strong SCHEMBL5696247 | 0.79 | LMNA (0.58) | HSD17B10ALDH1A1CASP6CYP2C9CYP2C19 | |
| SCHEMBL16628504 | 0.79 | LMNA (0.58) | HSD17B10ALDH1A1CASP6CYP2C9CYP2C19 | |
| SCHEMBL1433007 | 0.79 | LMNA (0.58) | HSD17B10ALDH1A1CASP6CYP2C9CYP2C19 | |
| SCHEMBL8782088 | 0.79 | LMNA (0.58) | HSD17B10ALDH1A1CASP6CYP2C9CYP2C19 | |
| SCHEMBL5696255 | 0.79 | LMNA (0.58) | HSD17B10ALDH1A1CASP6CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8377938-B2 | Phenoxypyridine derivative salts and crystals thereof, and process for preparing the same | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2013-02-19 | — | — | US | disclosed |
| US-7790885-B2 | Process for preparing phenoxypyridine derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-09-07 | — | — | US | disclosed |
| US-20080318924-A1 | PHENOXYPYRIDINE DERIVATIVE SALTS AND CRYSTALS THEREOF, AND PROCESS FOR PREPARING THE SAME | EISAI R&D MANAGEMENT CO., LTD (JP) | 2008-12-25 | — | — | US | disclosed |
| US-20080214815-A1 | Process for preparing phenoxypyridine derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2008-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080318924-A1 | PHENOXYPYRIDINE DERIVATIVE SALTS AND CRYSTALS THEREOF, AND PROCESS FOR PREPARING THE SAME | HGF, MET, FLT1 | HSD17B10 1574/4885ALDH1A1 599/4885CASP6 2971/4885 |
| US-20080214815-A1 | Process for preparing phenoxypyridine derivatives | FIP1L1, SKP1, TET2 | HSD17B10 4167/4885ALDH1A1 2045/4885CASP6 3570/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.